Experimental combo for rare lung cancer shows early promise but trial halted
NCT ID NCT04166734
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested the drug pembrolizumab (Keytruda) combined with targeted radiation (SBRT) in 5 people with advanced malignant pleural mesothelioma, a rare cancer of the lung lining. The goal was to check safety and find the right dose. The study was terminated early, so we have limited data on how well it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pembrolizumab (Keytruda) and stereotactic body radiotherapy (SBRT)
- What this could lead to
- If successful, this combination could offer a new treatment option for advanced mesothelioma patients who have run out of standard therapies.
- What could go wrong
- This was a very early phase 1 trial with only 5 participants and has been terminated, so results are limited. The combination may cause severe side effects like fever or bleeding, and it is unclear if it will improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT PLEURAL MESOTHELIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beatson West of Scotland Cancer Centre
Glasgow, G12 0YN, United Kingdom
-
Royal Marsden NHS Foundation Trust
Chelsea, United Kingdom